# Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)

Study · id `cardio:ct-nct01274559` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01274559](<https://clinicaltrials.gov/study/NCT01274559>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01274559

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1173 participants.

## Technical summary

Registry record NCT01274559. Randomized; double masking; primary purpose treatment. Start 2011-03-01 (actual); primary completion 2013-02-26 (actual). Results posted on 2014-03-14.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1173 participants (enrolled count; ClinicalTrials.gov record NCT01274559, source copy `cardio:ctgov-nct01274559-2024-05-22`, retrieved 2026-10-31)
- Started: 2011-03-01 (actual) (ClinicalTrials.gov record NCT01274559, source copy `cardio:ctgov-nct01274559-2024-05-22`, retrieved 2026-10-31)
- Primary completion: 2013-02-26 (actual) (ClinicalTrials.gov record NCT01274559, source copy `cardio:ctgov-nct01274559-2024-05-22`, retrieved 2026-10-31)
- Completion: 2013-02-26 (actual) (ClinicalTrials.gov record NCT01274559, source copy `cardio:ctgov-nct01274559-2024-05-22`, retrieved 2026-10-31)
- Results first posted: 2014-03-14 (ClinicalTrials.gov record NCT01274559, source copy `cardio:ctgov-nct01274559-2024-05-22`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01274559-2024-05-22`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)
- Condition: Primary Hypercholesterolemia
- Condition: Mixed Dyslipidemia
- Intervention (Drug): Extended-release niacin/laropiprant (ERN/LRPT)
- Intervention (Drug): Placebo
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

## Provenance

Content hash: 871e643062f575c8584c54293be3a2af74c78eca7e34620c98b273c63dcd4f25
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
